Jonathan Rosenberg
乔纳森·罗森伯格
MD
Chief, Genitourinary Oncology Service泌尿生殖肿瘤科主任
👥Biography 个人简介
Jonathan Rosenberg is a leading bladder cancer oncologist at MSKCC, pioneering immunotherapy and antibody-drug conjugate trials. He led pivotal studies on atezolizumab and enfortumab vedotin that redefined urothelial carcinoma treatment standards globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Bladder Cancer Immunotherapy
Led clinical development of atezolizumab for urothelial carcinoma, establishing PD-L1 inhibition as a standard second-line therapy and transforming outcomes for platinum-ineligible patients.
Antibody-Drug Conjugates
Drove enfortumab vedotin trials in metastatic urothelial cancer, demonstrating unprecedented response rates in heavily pretreated patients and winning FDA breakthrough designation.
Representative Works 代表性著作
Atezolizumab in Urothelial Carcinoma after Platinum Treatment
The Lancet (2016)
Landmark phase II trial establishing atezolizumab efficacy in platinum-refractory bladder cancer.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
New England Journal of Medicine (2021)
Phase III EV-301 trial showing survival benefit of enfortumab vedotin over chemotherapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 乔纳森·罗森伯格 的研究动态
Follow Jonathan Rosenberg's research updates
留下邮箱，当我们发布与 Jonathan Rosenberg（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment